LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

Inicio・Lista de Acciones・Ascendis Pharma A-S ADR

Ascendis Pharma A-S ADR

Cerrado

SectorSalud

230.47 1.95

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

224.45

Máximo

231.2

Métricas clave
By Trading Economics
Ingresos	28M -33M
Ventas	32M 245M
Margen de beneficio	-13.56
Empleados	1,189
EBITDA	68M 15M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 meses	+29.69% upside

Dividendos
By Dow Jones
Próximas Ganancias	30 abr 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	1.2B 15B
Apertura anterior	228.52
Cierre anterior	230.47

Noticias sobre sentimiento de mercado

By Acuity

54%

46%

282 / 351 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

157.66 / 167.29 Soporte y Resistencia

Ascendis Pharma A-S ADR Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

16 mar 2026, 21:37 UTC

Adquisiciones, fusiones, absorciones

Lensar and Alcon Agree to Terminate Merger

16 mar 2026, 19:06 UTC

Noticias de Eventos Importantes

Mideast Loses 12 Million Boe/d Following Hormuz Closure: Rystad -- OPIS

16 mar 2026, 17:44 UTC

Adquisiciones, fusiones, absorciones

Novartis Issues Debt Offering to Help Fund $12 Billion Acquisition of Avidity Biosciences

16 mar 2026, 23:46 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

16 mar 2026, 23:46 UTC

Charlas de Mercado

Nikkei May Rise After Oil Prices Decline -- Market Talk

16 mar 2026, 23:37 UTC

Charlas de Mercado

Gold Edges Higher on Possible Technical Recovery -- Market Talk

16 mar 2026, 23:05 UTC

Charlas de Mercado

Slumping Consumer Confidence Highlights Risk Around RBA Hike -- Market Talk

16 mar 2026, 21:56 UTC

Charlas de Mercado

DUG Technology's Stock Fall Creates Opportunity -- Market Talk

16 mar 2026, 21:41 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Global Equities Roundup: Market Talk

16 mar 2026, 21:41 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Clouds Gather Over Auckland Intl Airport as Airlines Up Fares -- Market Talk

16 mar 2026, 20:59 UTC

Adquisiciones, fusiones, absorciones

Alcon: Transaction Unattractive to Pursue Further in Light of FTC's Opposition

16 mar 2026, 20:59 UTC

Adquisiciones, fusiones, absorciones

Alcon: Delay and Associated Costs of Extended Regulatory Review Has Rendered Deal Unattractive to Pursue Further

16 mar 2026, 20:59 UTC

Adquisiciones, fusiones, absorciones

Alcon Entered Agreement With LENSAR to Terminate Merger Agreement

16 mar 2026, 20:57 UTC

Adquisiciones, fusiones, absorciones

Alcon and LENSAR, Inc. Agree to Terminate Merger Agreement

16 mar 2026, 20:51 UTC

Adquisiciones, fusiones, absorciones

Nvidia-Backed Nscale Plans Huge Data Center Cluster in West Virginia -- WSJ

16 mar 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

16 mar 2026, 20:50 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Energy & Utilities Roundup: Market Talk

16 mar 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

16 mar 2026, 20:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

16 mar 2026, 19:53 UTC

Noticias de Eventos Importantes

U.S. Allies Rebuff Trump's Demand for Help Opening Strait of Hormuz -- WSJ

16 mar 2026, 19:43 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

16 mar 2026, 19:43 UTC

Charlas de Mercado

Nvidia Sees $1 Trillion in Blackwell, Rubin Orders Through 2027 -- Market Talk

16 mar 2026, 19:37 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Natural Gas Follows Oil Prices Lower -- Market Talk

16 mar 2026, 19:20 UTC

Noticias de Eventos Importantes

Stock Market Today: Dow Jumps, Brent Crude Pulls Back From $105 -- WSJ

16 mar 2026, 19:17 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Crude Oil Sinks on Signals from Strait of Hormuz -- Market Talk

16 mar 2026, 19:00 UTC

Charlas de Mercado

Bank of Canada Needs Dovish Approach Based on Weak Data -- Market Talk

16 mar 2026, 18:23 UTC

Charlas de Mercado

LME Restarts Trading After Outage -- Market Talk

16 mar 2026, 17:36 UTC

Noticias de Eventos Importantes

Oil Prices Fall as Trump Says Hormuz Help Is Coming. Tankers Getting Through, Bessent Adds. -- Barrons.com

16 mar 2026, 17:19 UTC

Charlas de Mercado

Grains Sink as Investors Steer Toward Equities -- Market Talk

16 mar 2026, 17:14 UTC

Noticias de Eventos Importantes

Trump Ends News Conference

Comparación entre iguales

Cambio de precio

Ascendis Pharma A-S ADR Esperado

Precio Objetivo

By TipRanks

29.69% repunte

Estimación a 12 meses

Media 293.08 USD 29.69%

Máximo 342 USD

Mínimo 255 USD

De acuerdo con 13 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ascendis Pharma A-S ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

13 ratings

Comprar

Mantener

Vender

De acuerdo con 13 analistas que ofrecen calificaciones bursátiles a para Ascendis Pharma A-S ADR Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

157.66 / 167.29Soporte y Resistencia

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

All events are bullish.

Sentimiento

By Acuity

282 / 351 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Ascendis Pharma A-S ADR

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.